Breast Cancer Update Home - Oncology Leader Commentary

Home: Oncology Leader Commentary: George W. Sledge, MD

Click on the topic below for comments by Dr George W. Sledge to comment on. You will also find links to related articles and clinical trials.

Tyrosine kinase inhitors, antiangiogenic agents
Tyrosine kinase inhitors
Herceptin versus the new tyrosine kinase inhibitors
Combining Herceptin and a tyrosine kinase inhibitors
Combining Herceptin and an Aromotase Inhibitor
Current trends in systemic therapy
Management of metastatic breast cancer
Use of Herceptin in metastatic disease
Assessing HER2 status
Herceptin as a first-line single agent
Endocrine therapy versus cytotoxic therapy of metastatic disease
Tamoxifen rechallenge in patients with prior adjuvant tamoxifen
Chosing an aromatase inhibitor
Aromatase inhibitors as first-line therapy of metastatic disease
Overview of the science of breast cancer medicine.

Home

Patrick I. Borgen, MD

Aman Buzdar, MD

Nancy E. Davidson, MD

J. Michael Dixon, MD

Armando Giuliano, MD

I. Craig Henderson, MD

David Krag, MD

Gershon Locker, MD

Charles Loprinzi, MD

Richard Margolese, MD

Monica Morrow, MD

C Kent Osborne, MD

Sir Richard Peto, FRS

Kathy I. Pritchard, MD

John F. Robertson, MD,FRCS

Andrew D. Seidman, MD

George W. Sledge, MD

Home · Contact us

Terms of use and general disclaimer